Bora Pharmaceuticals Co., Ltd. (TPE:6472)

Market Cap	46.10B -34.0%
Revenue (ttm)	19.01B +9.1%
Net Income	2.98B -22.6%
EPS	15.81 -42.1%
Shares Out	126.99M
PE Ratio	15.62
Forward PE	11.04
Dividend	10.00 (2.48%)
Ex-Dividend Date	Jun 20, 2025

Volume	4,200,322
Average Volume	1,211,582
Open	335.00
Previous Close	363.00
Day's Range	330.50 - 374.50
52-Week Range	336.00 - 795.00
Beta	0.57
RSI	24.46
Earnings Date	May 19, 2026

About Bora Pharmaceuticals

Bora Pharmaceuticals Co., Ltd. engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. The company operates through Sales, CDMO, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs. The company also offers contract development and manufacturing services and technical services for the development of pharmaceutical products. In addition, it provides Western pharmaceuticals, including central nervous system medications, antibioti...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2007
• Country: Taiwan
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6472

Financial Performance

In 2025, Bora Pharmaceuticals's revenue was 19.01 billion, an increase of 9.11% compared to the previous year's 17.43 billion. Earnings were 2.98 billion, a decrease of -22.61%.